Osborne, Wendy

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 195

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 41

A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams

Stenson, C. L., Vidrine, J., Dewhurst, F., Osborne, W., Menne, T., & Stocker, R. (2023) · Palliative Medicine

CAR-T cell therapy researchCancer survivorship and care

Cited by 34

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study

Santarsieri, A., Mitchell, E., Pham, M. H., Sanghvi, R., Jablonski, J., Lee-Six, H., Sturgess, K., Brice, P., Menne, T. F., Osborne, W., et al. (2025) · The Lancet Oncology

Lymphoma Diagnosis and TreatmentMultiple and Secondary Primary Cancers

Cited by 12